EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Enliven Therapeutics Inc. (ELVN) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Enliven Therapeutics Inc. $6.26, price $46.97, upside -86.7%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US29337E1029

ET Enliven Therapeutics Inc. logo Thin data Sep 24, 2026

Enliven Therapeutics Inc.

ELVN · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $6.26 · Strongly overvalued (−86.7%)
!Quality 25/100
!negative free cash flow
!Mixed vs. peers (3/7)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch Enliven Therapeutics Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$61.15 $3.96 Fair Value $6.26 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $3.96 – $61.15 · fair‑value band $4.13 – $7.82 · the $46.97 price screens above the $6.26 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Enliven Therapeutics in your weekly email

Every Wednesday you see whether Enliven Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

Show more

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Stock analysis

Enliven Therapeutics Inc. (ELVN) currently trades at $46.97, while our model-based Fair Value estimate is $6.26, 86.7% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: $4.13 (bear) to $7.82 (bull), the price of $46.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Enliven Therapeutics Inc. reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$104M in FY2025.

Key figures

Market cap $4.5B · EPS (TTM) $−1.65 · Return on equity −15.3% · Return on assets (EBIT) −31.3% · Free cash flow −$70.5M · Net cash $98.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).

What moves the price

The share trades about 23% below its 52-week high and 210% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, ELVN screens richer than that median.

Fair Value models

Bear $4.13 Fair Value $6.26 Bull $7.82
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.14 $4.20 $6.27 51
All 1 models by family
Asset-Based
NCAV (Graham) $3.14 $4.20 $6.27 51

Open the full fair value analysis →

Notify me when ELVN reaches fair value

Put ELVN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 32 · Market factors (momentum, volatility) 67

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 12
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 69
Price trend over the last 3–12 months (market factor)
52W Momentum 85
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ELVN screens overvalued: fair value 87% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (50 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Enliven Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −86.5% · Bottom 25%
Profitability
Return on assets −11.0% · Below median
Operating margin (TTM) 0.0% · Above median
Growth and dividend
Revenue growth 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 9.73× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Enliven Therapeutics Inc. · Fair Value
$6.26 −87%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Enliven Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ELVN

Frequently asked questions

Is Enliven Therapeutics Inc. (ELVN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $6.26 versus a price of $46.97, about −87% upside (overvalued).
What is the fair value of ELVN?
Our model-based fair value for Enliven Therapeutics Inc. is $6.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: $46.97.
What is the quality score of ELVN?
Enliven Therapeutics Inc. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enliven Therapeutics Inc. (ELVN)?
Our model-based price target is the fair value of $6.26 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $4.13, optimistic scenario $7.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Enliven Therapeutics Inc. stock forecast for 2026?
Our models put fair value at $6.26, about −87% upside versus a price of $46.97 (overvalued). Cautious scenario $4.13, optimistic scenario $7.82. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Enliven Therapeutics Inc. (ELVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enliven Therapeutics Inc. it is $6.26 per share (as of Sep 24, 2026), against a price of $46.97. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Enliven Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ELVN trades above its calculated fair value: price $46.97, fair value $6.26, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELVN?
No. The price is what the market pays today ($46.97); the fair value is what the company's own numbers justify ($6.26). For Enliven Therapeutics Inc. the two are $40.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enliven Therapeutics Inc. worth?
The market values Enliven Therapeutics Inc. at about $4.5B (market capitalisation, as of Sep 24, 2026). Per share that is $46.97; our models calculate a fair value of $6.26 per share.
What do the bullish and bearish scenarios say about ELVN?
Our models span a range for Enliven Therapeutics Inc.: cautious scenario $4.13, base $6.26, optimistic $7.82 per share (as of Sep 24, 2026, price $46.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enliven Therapeutics Inc. (ELVN)?
Balance-sheet figures for Enliven Therapeutics Inc. (as of Sep 24, 2026): return on equity −15.3%. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is ELVN from its 52-week high?
Enliven Therapeutics Inc. trades at $46.97, about 23% below its 52-week high of $61.15 and 210% above the low of $15.14 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $6.26 is for.
Which stocks are comparable to Enliven Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enliven Therapeutics Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price $46.97, calculated fair value $6.26 (−87%), Quality Score 25/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELVN calculated?
We run Enliven Therapeutics Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Enliven Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enliven Therapeutics Inc. (ELVN)?
The closing price on Oct 2, 2026 was $46.97. Our model-based fair value is $6.26, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enliven Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($7.82). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($4.13 to $7.82) leaves room in how you read the outcome.

Key figures of Enliven Therapeutics Inc.

How large is the market capitalisation of Enliven Therapeutics Inc. (ELVN)?
The market capitalisation of Enliven Therapeutics Inc. is $4.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Enliven Therapeutics Inc. (ELVN)?
Earnings per share at Enliven Therapeutics Inc. are $−1.65. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Enliven Therapeutics Inc. (ELVN)?
The return on equity (ROE) of Enliven Therapeutics Inc. is −15.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enliven Therapeutics Inc. (ELVN)?
On an EBIT basis the return on assets of Enliven Therapeutics Inc. is −31.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Enliven Therapeutics Inc. (ELVN) generate?
The free cash flow of Enliven Therapeutics Inc. is −$70.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Enliven Therapeutics Inc. (ELVN) hold?
Enliven Therapeutics Inc. holds more cash than debt, $98.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Enliven Therapeutics Inc. in the live analysis

One click puts Enliven Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.